HK inno.N Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacodynamic Properties of CJ-12420 on Evening Dosing

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CJ-12420 100mg
Drug: CJ-12420 200mg
Drug: CJ-12420 50mg
Drug: Dexlansoprazole 60 MG

First Posted Date: 2017-02-06

Last Posted Date: 2017-02-06

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 24

Registration Number: NCT03043521

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration

Phase 1

Completed

Conditions: Drug Interaction
Pharmacokinetic
Pharmacodynamic

Interventions: Drug: CJ-12420 100mg
Drug: CLR 500mg
Drug: CJ-12420 50mg
Drug: Pantoprazole 40mg
Drug: AMX 1g

First Posted Date: 2017-01-06

Last Posted Date: 2017-05-12

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 60

Registration Number: NCT03011996

Locations: 🇰🇷
Inje University Busan Baik Hospital, Busan, Korea, Republic of

To Investigate Pharmacokinetics and Pharmacodynamics of CJ-12420 After Single and Multiple Dose Administration

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CJ-12420 100mg(HP+)
Drug: CJ-12420 50mg(HP+)
Drug: CJ-12420 50mg(HP-)
Drug: CJ-12420 100mg(HP-)

First Posted Date: 2017-01-04

Last Posted Date: 2017-01-20

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 16

Registration Number: NCT03009760

Pharmacokinetics Study of CJ-30060 After Single Dose Administration in Health Male Volunteers

Phase 1

Completed

Conditions: Hyperlipidemias
Hypertension

Interventions: Drug: CJ-30060
Drug: Exforge tab 5/160mg, Crestor tab 10mg

First Posted Date: 2017-01-04

Last Posted Date: 2017-01-04

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 52

Registration Number: NCT03009474

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

Phase 3

Completed

Conditions: Erosive Esophagitis

Interventions: Drug: CJ-12420 100mg QD
Drug: CJ-12420 50mg QD
Drug: Esomeprazole 40mg

First Posted Date: 2016-12-30

Last Posted Date: 2017-09-12

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 302

Registration Number: NCT03006874

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

A Study to Compare the Pharmacokinetic Characteristics of CJ-12420

Phase 1

Completed

Conditions: Erosive Esophagitis

Interventions: Drug: CJ-12420 formulation 1
Drug: CJ-12420 formulation 2

First Posted Date: 2016-12-16

Last Posted Date: 2016-12-16

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 12

Registration Number: NCT02995239

Locations: 🇰🇷
Chonbuk National University Hospital, Chonju, Korea, Republic of

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer

Phase 3

Completed

Conditions: Gastric Ulcer

Interventions: Drug: CJ-12420 50 mg QD
Drug: Lansoprazole 30 mg QD
Drug: CJ-12420 100 mg QD

First Posted Date: 2016-05-04

Last Posted Date: 2019-08-22

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 306

Registration Number: NCT02761512

Locations: 🇰🇷
Kyung Hee University Medical Center, Seoul, Korea, Republic of
🇰🇷
Catholic Univ. Seoul St. Mary Hospita, Seoul, Korea, Republic of

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease

Phase 3

Completed

Conditions: Non-erosive Reflux Disease

Interventions: Drug: CJ-12420 100mg
Drug: Placebo
Drug: CJ-12420 50mg

First Posted Date: 2015-09-22

Last Posted Date: 2018-04-04

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 324

Registration Number: NCT02556021

Locations: 🇰🇷
Yeouido St.Mary's Hospital, Seoul, Korea, Republic of

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

Phase 3

Completed

Conditions: Erosive Esophagitis

Interventions: Drug: CJ-12420 100 mg QD
Drug: Esomeprazole 40 mg QD

First Posted Date: 2015-05-29

Last Posted Date: 2016-12-15

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 280

Registration Number: NCT02456935

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor 20mg/Glucophage SR 750mg

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Atorvastatin 20mg and Metformin SR 750mg
Drug: CJ-30056 20/750mg

First Posted Date: 2015-03-04

Last Posted Date: 2016-12-30

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 42

Registration Number: NCT02378441

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy